622 related articles for article (PubMed ID: 26766908)
1. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
Li X; Wu M; Pan L; Shi J
Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
3. A dual-sensitive mesoporous silica nanoparticle based drug carrier for cancer synergetic therapy.
Zhang J; Shen B; Chen L; Chen L; Meng Y; Feng J
Colloids Surf B Biointerfaces; 2019 Mar; 175():65-72. PubMed ID: 30522009
[TBL] [Abstract][Full Text] [Related]
4. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
5. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
[TBL] [Abstract][Full Text] [Related]
6. Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells.
Liu Y; Chen Q; Xu M; Guan G; Hu W; Liang Y; Zhao X; Qiao M; Chen D; Liu H
Int J Nanomedicine; 2015; 10():1855-67. PubMed ID: 25834425
[TBL] [Abstract][Full Text] [Related]
7. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
8. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression.
Pan L; Liu J; He Q; Shi J
Adv Mater; 2014 Oct; 26(39):6742-8. PubMed ID: 25159109
[TBL] [Abstract][Full Text] [Related]
9. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
Sengupta S; Eavarone D; Capila I; Zhao G; Watson N; Kiziltepe T; Sasisekharan R
Nature; 2005 Jul; 436(7050):568-72. PubMed ID: 16049491
[TBL] [Abstract][Full Text] [Related]
10. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
12. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
13. A general strategy for dual-triggered combined tumor therapy based on template semi-graphitized mesoporous silica nanoparticles.
Wang Y; Wang K; Yan X; Huang R
Adv Healthc Mater; 2014 Apr; 3(4):485-9. PubMed ID: 23997032
[TBL] [Abstract][Full Text] [Related]
14. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
[TBL] [Abstract][Full Text] [Related]
15. Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
Chakravarty R; Goel S; Hong H; Chen F; Valdovinos HF; Hernandez R; Barnhart TE; Cai W
Nanomedicine (Lond); 2015; 10(8):1233-46. PubMed ID: 25955122
[TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-tumor activity of a drug through pH-triggered release and dual targeting by calcium phosphate-covered mesoporous silica vehicles.
Liu J; Hu X; Jin S; Liang XJ; Ma X
J Mater Chem B; 2022 Jan; 10(3):384-395. PubMed ID: 34935843
[TBL] [Abstract][Full Text] [Related]
17. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy.
Rapoport N; Gao Z; Kennedy A
J Natl Cancer Inst; 2007 Jul; 99(14):1095-106. PubMed ID: 17623798
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
20. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
